These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 6219298)
21. Intracarotid tumor necrosis factor-alpha administration increases the blood-brain barrier permeability in cerebral cortex of the newborn pig: quantitative aspects of double-labelling studies and confocal laser scanning analysis. Abraham CS; Deli MA; Joo F; Megyeri P; Torpier G Neurosci Lett; 1996 Apr; 208(2):85-8. PubMed ID: 8859896 [TBL] [Abstract][Full Text] [Related]
22. Enhancement of CNS penetration of methotrexate by hyperosmolar intracarotid mannitol or carcinomatous meningitis. Hasegawa H; Allen JC; Mehta BM; Shapiro WR; Posner JB Neurology; 1979 Sep; 29(9 Pt 1):1280-6. PubMed ID: 573408 [TBL] [Abstract][Full Text] [Related]
23. Little effect of dimethyl sulfoxide on blood-brain barrier to dopamine. Walters A; Jackson-Lewis V; Fahn S Experientia; 1984 Aug; 40(8):859-61. PubMed ID: 6468603 [TBL] [Abstract][Full Text] [Related]
24. Intracarotid dehydrocholate infusion: a new method for prolonged reversible blood-brain barrier disruption. Spigelman MK; Zappulla RA; Malis LI; Holland JF; Goldsmith SJ; Goldberg JD Neurosurgery; 1983 Jun; 12(6):606-12. PubMed ID: 6877542 [TBL] [Abstract][Full Text] [Related]
25. Intracarotid infusions of protamine sulfate disrupt the blood-brain barrier of rabbits. Strausbaugh LJ Brain Res; 1987 Apr; 409(2):221-6. PubMed ID: 3580873 [TBL] [Abstract][Full Text] [Related]
26. Etoposide induced blood-brain barrier disruption in rats: duration of opening and histological sequelae. Spigelman MK; Zappulla RA; Strauchen JA; Feuer EJ; Johnson J; Goldsmith SJ; Malis LI; Holland JF Cancer Res; 1986 Mar; 46(3):1453-7. PubMed ID: 3510725 [TBL] [Abstract][Full Text] [Related]
27. Modification of the blood-brain barrier permeability by vinorelbine: effect of intracarotid infusion compared with intravenous infusion. Mouchard-Delmas C; Gourdier B; Vistelle R; Wiczewski M Anticancer Drugs; 1996 Feb; 7(2):213-9. PubMed ID: 8740728 [TBL] [Abstract][Full Text] [Related]
28. Blood-brain barrier disruption using mannitol: time course and electron microscopy studies. Cosolo WC; Martinello P; Louis WJ; Christophidis N Am J Physiol; 1989 Feb; 256(2 Pt 2):R443-7. PubMed ID: 2492773 [TBL] [Abstract][Full Text] [Related]
29. [The effect on the tumor vessel permeability by hyperosmotic blood brain barrier disruption]. Miyagami M; Tazoe M; Kagawa Y; Tsubokawa T No To Shinkei; 1988 Sep; 40(9):875-82. PubMed ID: 3142506 [TBL] [Abstract][Full Text] [Related]
30. Evaluation of pharmacokinetics of 4-borono-2-(18)F-fluoro-L-phenylalanine for boron neutron capture therapy in a glioma-bearing rat model with hyperosmolar blood-brain barrier disruption. Hsieh CH; Chen YF; Chen FD; Hwang JJ; Chen JC; Liu RS; Kai JJ; Chang CW; Wang HE J Nucl Med; 2005 Nov; 46(11):1858-65. PubMed ID: 16269600 [TBL] [Abstract][Full Text] [Related]
31. Inconsistent blood brain barrier disruption by intraarterial mannitol in rabbits: implications for chemotherapy. Joshi S; Ergin A; Wang M; Reif R; Zhang J; Bruce JN; Bigio IJ J Neurooncol; 2011 Aug; 104(1):11-9. PubMed ID: 21153681 [TBL] [Abstract][Full Text] [Related]
32. Osmotic opening of the blood-brain barrier to methotrexate in the rat. Ohno K; Fredericks WR; Rapoport SI Surg Neurol; 1979 Oct; 12(4):323-8. PubMed ID: 524251 [TBL] [Abstract][Full Text] [Related]
33. Pharmacology and neurotoxicity of cis-diamminedichloroplatinum, bleomycin, 5-fluorouracil, and cyclophosphamide administration following osmotic blood-brain barrier modification. Neuwelt EA; Barnett PA; Glasberg M; Frenkel EP Cancer Res; 1983 Nov; 43(11):5278-85. PubMed ID: 6193870 [TBL] [Abstract][Full Text] [Related]
34. Electroencephalographic consequences of sodium dehydrocholate-induced blood-brain barrier disruption: Part 1. Acute and chronic effects of intracarotid sodium dehydrocholate. Zappulla RA; Spigelman MK; Omsberg E; Rosen JJ; Malis LI; Holland JF Neurosurgery; 1985 May; 16(5):630-8. PubMed ID: 4000434 [TBL] [Abstract][Full Text] [Related]
35. Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma. Neuwelt EA; Howieson J; Frenkel EP; Specht HD; Weigel R; Buchan CG; Hill SA Neurosurgery; 1986 Oct; 19(4):573-82. PubMed ID: 3097567 [TBL] [Abstract][Full Text] [Related]
36. Quantitative analysis of hyperosmotic and hypothermic blood-brain barrier opening. Ikeda M; Nagashima T; Bhattacharjee AK; Kondoh T; Kohmura E; Tamaki N Acta Neurochir Suppl; 2003; 86():559-63. PubMed ID: 14753506 [TBL] [Abstract][Full Text] [Related]
37. Effect of osmotic blood-brain barrier disruption on methotrexate pharmacokinetics in the dog. Neuwelt EA; Frenkel EP; Rapoport S; Barnett P Neurosurgery; 1980 Jul; 7(1):36-43. PubMed ID: 6774280 [TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of tumor cell exposure to [14C]methotrexate after intracarotid administration without and with hyperosmotic opening of the blood-brain and blood-tumor barriers in rat brain tumors: a quantitative autoradiographic study. Shapiro WR; Voorhies RM; Hiesiger EM; Sher PB; Basler GA; Lipschutz LE Cancer Res; 1988 Feb; 48(3):694-701. PubMed ID: 3335031 [TBL] [Abstract][Full Text] [Related]
39. Platelet activating factor induces transient blood-brain barrier opening to facilitate edaravone penetration into the brain. Fang W; Zhang R; Sha L; Lv P; Shang E; Han D; Wei J; Geng X; Yang Q; Li Y J Neurochem; 2014 Mar; 128(5):662-71. PubMed ID: 24164378 [TBL] [Abstract][Full Text] [Related]
40. Effect of intracarotid etoposide on opening the blood-brain barrier. Spigelman MK; Zappulla RA; Goldberg JD; Goldsmith SJ; Marotta D; Malis LI; Holland JF Cancer Drug Deliv; 1984; 1(3):207-11. PubMed ID: 6399858 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]